A Phase II study of TSU-68 in patient with hepatocellular carcinoma

Phase 2

• Conditions: Hepatocellular Carcinoma

• Registration Number: JPRN-jRCT2080221054
• Lead Sponsor: Taiho Pharmaceutical Co., Ltd.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2010-04-01
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Sex: All
• Target Recruitment: 100

Inclusion Criteria

1)20 years or older.
2)Histopathologically confirmed HCC or diagnosed as HCC by the CT imaging.
3)Not indicated to treatment with curative surgery or percutaneous ablation(such as RFA, PEIT or PMCT).
4)Adequate oral intake.
5)Life expectancy of at least 3 months.
6)P.S.:0-2

Exclusion Criteria

1)Patient has ascites, pleural effusions or pericardial fluid requiring drainage .
2)Patient has clinical symptoms of hepatic encephalopathy.
3)Patient has active or uncontrolled clinically serious infection excluding
chronic hepatitis .
4)Patient has active double cancer.
5)Have participated in other clinical trials within 4 weeks prior to registration.

Study & Design

• Study Type: Interventional
• Study Design: Not specified